Methylenetetrahydrofolate reductase polymorphism in Kawasaki disease

Abstract Background: A genetic aberration in the 5,10‐methylenetetrahydrofolate reductase (MTHFR) gene (677 C to T substitution) has been shown to result in reduced enzyme activity. The hypothesis tested in the present study was that a higher proportion of Kawasaki disease (KD) patients with coronary artery lesions (CAL) would have the T677 allele compared with patients without CAL and healthy subjects.

[1]  S. Sato,et al.  High incidence of angiotensin I converting enzyme genotype II in Kawasaki disease patients with coronary aneurysm , 1997, European Journal of Pediatrics.

[2]  R. Matthews,et al.  A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase , 1995, Nature Genetics.

[3]  J. Loscalzo,et al.  Homocysteine, EDRF, and endothelial function. , 1996, The Journal of nutrition.

[4]  G. Boers.  Hyperhomocysteinemia as a Risk Factor for Arterial and Venous Disease. A Review of Evidence and Relevance , 1997, Thrombosis and Haemostasis.

[5]  T. Arinami,et al.  Methylenetetrahydrofolate reductase polymorphism and pre-eclampsia. , 1997, Journal of medical genetics.

[6]  K. Kario,et al.  A common mutation in methylenetetrahydrofolate reductase gene among the Japanese population , 1996, Japanese Journal of Human Genetics.

[7]  B. McManus,et al.  Homocyst(e)ine and coronary artery disease. Clinical evidence and genetic and metabolic background. , 1997, Archives of internal medicine.

[8]  D. Leung.  The Potential Role of Cytokine‐Mediated Vascular Endothelial Activation in the Pathogenesis of Kawasaki Disease , 1991, Acta paediatrica Japonica : Overseas edition.

[9]  D. Cole,et al.  Clinical chemistry and molecular biology of homocysteine metabolism: an update. , 1997, Clinical biochemistry.

[10]  H. Nakano,et al.  Pathological features of coronary arteries in children with Kawasaki disease in which coronary arterial aneurysm was absent at autopsy. Quantitative analysis. , 1988, Circulation.

[11]  H. Nakano,et al.  Intravenous γ‐Globulin for Kawasaki Disease , 1991 .

[12]  H. Tsukahara,et al.  Endogenous nitric oxide production in Kawasaki disease. , 1997, Scandinavian Journal of Clinical and Laboratory Investigation.

[13]  L. Benson,et al.  Outcome of coronary artery aneurysms after Kawasaki disease. , 1992, The Journal of pediatrics.

[14]  S. Shulman,et al.  Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose. , 1997, The Journal of pediatrics.

[15]  Y. Yazaki,et al.  Genetic polymorphism of 5,10-methylenetetrahydrofolate reductase (MTHFR) as a risk factor for coronary artery disease. , 1997, Circulation.

[16]  M. Takahashi.  The endothelium in Kawasaki disease: the next frontier. , 1998, The Journal of pediatrics.